Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.
Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
